Page 27 - 2022 DMOH Year-End Review Summary

Congratulations to Dr. Enrique Sanz Garcia for receiving the following grant and
award.

Hold’em for Life Oncology Fellowships Grant from the University of Toronto in June
2022 for the project “IO-KIN: ctDNA kinetics on patients treated with immuno-
therapy”.
Residents Novartis Oncology Young Canadian Investigator Award in 2022 for the project

“ctDNA as an early biomarker of response to immunotherapy in early phase clin-
ical trials”.

Congratulations to Dr. Gordon Taylor Moffat for receiving the Hold’EM for Life
Oncology Fellowship Grant and the Royal College of Physicians of Canada Profes-
sional Development Grant for the project “Optimizing the Quality of Surveillance
in Patients with Completely Resected Gastroenteropancreatic Neuroendocrine
Tumours”.

Congratulations to Dr. Jesus Fuentes Antras for receiving the Novartis Oncology
Young Canadian Investigator (NOYCIA) Award for the project “Molecular charac-
terization of long-term and short-term survivors of pancreatic ductal adenocar-
cinoma”.

Fellows Congrats to Dr. Sofia Genta for receiving the following awards: (1) Novartis
Oncology Young Canadian Investigator Award for the project “Autoimmune
Panels as Predictors of Toxicity in Patients Treated with Immunotherapy (ALERT)”.
(2) Hold’em for life Oncology Fellowship Award from the Faculty of Medicine,
University of Toronto for the project “Combination of Atezolizumab and Oral Micro-
bial Intervention in Patients with Advanced Solid Tumors to Interrogate the Gut
Microbiota (CASSIN)”.

Congrats to Dr. Consolacion Molto Valiente for receiving the Spanish Society of
Medical Oncology Grant and the Hold’em for Life Oncology Fellowships Grant for
the project “Machine learning to estimate the real-world risk of 3-year disease
free survival in patients with residual, triple negative breast cancer after neoadju-
vant chemotherapy”.

Congratulations to Dr. Michael He, Postdoctoral Fellow, and supervisor Dr. Robert
Kridel for being awarded the PM George Knudson Memorial Fellowship Fund for
their project, “Targeting GNAS Sensitizes Diffuse Large B-cell Lymphoma to Histone
Deacetylase 2 Inhibition.”